12/19
08:01 am
mynz
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
High
Report
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
12/16
05:00 pm
mynz
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Medium
Report
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
12/12
08:00 pm
mynz
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Medium
Report
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
11/29
08:45 am
mynz
Mainz Biomed Announces Stock Split
High
Report
Mainz Biomed Announces Stock Split
11/25
08:02 am
mynz
Mainz Biomed (NASDAQ: MYNZ) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Medium
Report
Mainz Biomed (NASDAQ: MYNZ) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
11/12
09:00 am
mynz
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
High
Report
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
10/21
02:11 pm
mynz
Mainz Biomed B.V. GAAP EPS of -$0.49, revenue of $520.77M [Seeking Alpha]
Low
Report
Mainz Biomed B.V. GAAP EPS of -$0.49, revenue of $520.77M [Seeking Alpha]
10/21
08:01 am
mynz
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
10/8
08:01 am
mynz
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Medium
Report
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
10/1
08:01 am
mynz
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Medium
Report
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025